Dosing chart / Sexual & hormonal
PT-141 vs Kisspeptin-10
Dose, schedule, route and approval status side by side.
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.
| PT-141 | Kisspeptin-10 | |
|---|---|---|
| Status | FDA-approved | Clinical trials |
| Also known as | bremelanotide, Vyleesi | – |
| Typical dose | 1.75 mg | 100–200 mcg |
| How often | As needed | As needed |
| Schedule | As needed, at least 45 minutes before sex. No more than one dose in 24 hours or eight a month. | Reported as needed or daily. Research studies mostly use weight-based intravenous doses. |
| Daily equivalent | Not a daily drug | 100–200 mcg/day |
| Route | Subcutaneous | Subcutaneous |
| Duration | As needed | Unknown |
| Notes | Approved for low sexual desire in premenopausal women. Nausea is common, and it briefly raises blood pressure. Calculator values assume a compounded vial; the brand is an autoinjector. | Studied in small trials for fertility and sexual function. Continuous exposure can suppress, not boost, hormone release. |
This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the PT-141 and Kisspeptin-10 pages.
Advertisement